Skip to main content

Animations

Pieter J. Gaillard, PhD

Chief Scientific Officer

Location: Leiden Netherlands

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";}

Pieter obtained an MSc degree in biomedical sciences from Utrecht University, and a PhD degree in pharmacology from Leiden University at the lab of Prof. Douwe Breimer. He is an award-winning researcher who published in several high-ranking journals. Pieter pioneered the development of a Blood-Brain Barrier model in tissue-cultured cells. Based on his unique know-how, he founded to-BBB in 2003. With his team, he successfully raised five rounds of investments – from seed capital to Series B – to build and grow the company. In 2008, he licensed the G-Technology® from Taiwanese research institute ITRI as the company’s new proprietary brain delivery platform. He effectively led the company through discovery and preclinical phases of drug development, delivering lead product 2B3-101 in a clinical phase I/II trial in 2011. His decades of knowledge on brain diseases and experience with various pre-clinical models will guarantee successful project management and completion by industry standards.


Associated Grants

  • Attenuation of Neuroinflammation by Brain-targeted Liposomal Methylprednisolone (2B3-201) in Two Pre-clinical Models of Parkinson's Disease

    2012


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.